X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Edirol® Tablets 0.5 µg/0.75 µg (generic name: eldecalcitol, hereafter, Edirol Tablet) for an osteoporosis treatment (an active vitamin D3 preparation). Chugai manufactures Edirol Tablet and supplies to Towa.
Lead Product(s): Eldecalcitol
Therapeutic Area: Musculoskeletal Product Name: Edirol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Towa Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2022
Details:
Edirol (eldecalcitol), is an active vitamin D3 derivative created based on Chugai’s long-standing vitamin D research. Chugai takes responsibilities as a holder of the approval, Towa will be responsible for marketing and providing information on use of Edirol.
Lead Product(s): Eldecalcitol
Therapeutic Area: Musculoskeletal Product Name: Edirol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Towa Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
Chugai Pharmaceutical and Taisho Pharmaceutical announced termination of the agreement between both companies regarding co-marketing of Edirol® Capsules 0.5 µg and 0.75 µg, a treatment for osteoporosis for which Chugai has a marketing authorization.
Lead Product(s): Eldecalcitol
Therapeutic Area: Musculoskeletal Product Name: Edirol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination January 22, 2021
Details:
Chugai has obtained regulatory approval for eldecalcitol (product name: Edirol®), an active vitamin D3 derivative created by Chugai from the China National Medical Products Administration (NMPA).
Lead Product(s): Eldecalcitol
Therapeutic Area: Musculoskeletal Product Name: Edirol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
